Antimicrobial O-Alkyl Derivatives of Naringenin and Their Oximes Against Multidrug-Resistant Bacteria. 2020

Anna Duda-Madej, and Joanna Kozłowska, and Paweł Krzyżek, and Mirosław Anioł, and Alicja Seniuk, and Katarzyna Jermakow, and Ewa Dworniczek
Department of Microbiology, Faculty of Medicine, Wroclaw Medical University, Chałubińskiego 4, 50-368 Wrocław, Poland.

New antimicrobial agents are needed to address infections caused by multidrug-resistant bacteria. Here, we are reporting novel O-alkyl derivatives of naringenin and their oximes, including novel compounds with a naringenin core and O-hexyl chains, showing activity against clinical strains of clarithromycin-resistant Helicobacter pylori, vancomycin-resistant Enterococcus faecalis, methicillin-resistant Staphylococcus aureus, and beta-lactam-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The minimum inhibitory concentrations (MICs), which provide a quantitative measure of antimicrobial activity, were in the low microgram range for the selected compounds. Checkerboard assays for the most active compounds in combination with antibiotics revealed interactions that varied from synergistic to neutral.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010091 Oximes Compounds that contain the radical R2C Aldoximes,Hydroxyimino Compounds,Ketoxime,Ketoximes,Oxime,Compounds, Hydroxyimino
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D016480 Helicobacter pylori A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405). Campylobacter pylori,Campylobacter pylori subsp. pylori,Campylobacter pyloridis,Helicobacter nemestrinae
D044950 Flavanones A group of FLAVONOIDS characterized with a 4-ketone. 2-Phenyl-Benzopyran-4-Ones,2 Phenyl Benzopyran 4 Ones
D055624 Methicillin-Resistant Staphylococcus aureus A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS. MRSA,Methicillin Resistant Staphylococcus aureus
D024901 Drug Resistance, Multiple, Bacterial The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Drug Resistance, Extensive, Bacterial,Drug Resistance, Extensively, Bacterial,Extensive Antibacterial Drug Resistance,Extensively Antibacterial Drug Resistance,Multidrug Resistance, Bacterial,Multiple Antibacterial Drug Resistance,Bacterial Multidrug Resistance,Bacterial Multidrug Resistances,Resistance, Bacterial Multidrug
D040981 Acinetobacter baumannii A species of gram-negative, aerobic bacteria, commonly found in the clinical laboratory, and frequently resistant to common antibiotics. Bacterium anitratum

Related Publications

Anna Duda-Madej, and Joanna Kozłowska, and Paweł Krzyżek, and Mirosław Anioł, and Alicja Seniuk, and Katarzyna Jermakow, and Ewa Dworniczek
February 2019, Molecules (Basel, Switzerland),
Anna Duda-Madej, and Joanna Kozłowska, and Paweł Krzyżek, and Mirosław Anioł, and Alicja Seniuk, and Katarzyna Jermakow, and Ewa Dworniczek
September 2017, Molecules (Basel, Switzerland),
Anna Duda-Madej, and Joanna Kozłowska, and Paweł Krzyżek, and Mirosław Anioł, and Alicja Seniuk, and Katarzyna Jermakow, and Ewa Dworniczek
December 2013, Bioorganic & medicinal chemistry,
Anna Duda-Madej, and Joanna Kozłowska, and Paweł Krzyżek, and Mirosław Anioł, and Alicja Seniuk, and Katarzyna Jermakow, and Ewa Dworniczek
April 2014, Journal of the American Chemical Society,
Anna Duda-Madej, and Joanna Kozłowska, and Paweł Krzyżek, and Mirosław Anioł, and Alicja Seniuk, and Katarzyna Jermakow, and Ewa Dworniczek
September 2019, Pakistan journal of pharmaceutical sciences,
Anna Duda-Madej, and Joanna Kozłowska, and Paweł Krzyżek, and Mirosław Anioł, and Alicja Seniuk, and Katarzyna Jermakow, and Ewa Dworniczek
April 2023, ACS infectious diseases,
Anna Duda-Madej, and Joanna Kozłowska, and Paweł Krzyżek, and Mirosław Anioł, and Alicja Seniuk, and Katarzyna Jermakow, and Ewa Dworniczek
April 2020, Microorganisms,
Anna Duda-Madej, and Joanna Kozłowska, and Paweł Krzyżek, and Mirosław Anioł, and Alicja Seniuk, and Katarzyna Jermakow, and Ewa Dworniczek
January 2023, Frontiers in microbiology,
Anna Duda-Madej, and Joanna Kozłowska, and Paweł Krzyżek, and Mirosław Anioł, and Alicja Seniuk, and Katarzyna Jermakow, and Ewa Dworniczek
June 2009, Natural product reports,
Anna Duda-Madej, and Joanna Kozłowska, and Paweł Krzyżek, and Mirosław Anioł, and Alicja Seniuk, and Katarzyna Jermakow, and Ewa Dworniczek
November 2022, RSC medicinal chemistry,
Copied contents to your clipboard!